Mod­er­na starts up third HIV vac­cine tri­al, part­ner­ing with IAVI to study its shot in Africa

Ear­li­er this year, Mod­er­na and non­prof­it re­search group IAVI (In­ter­na­tion­al AIDS Vac­cine Ini­tia­tive) an­nounced that the first dos­es of an mR­NA an­ti-HIV vac­cine can­di­date had been ad­min­is­tered in a tri­al called IAVI G002. That was, at least some­what, in line with Mod­er­na CEO Stéphane Ban­cel’s goal for the com­pa­ny last year to launch three Phase I tri­als for an HIV pro­gram.

Based on re­sults from stud­ies in pre­vi­ous years (G001 launched in 2018), Mod­er­na and IAVI are now jump­ing in­to a new col­lab­o­ra­tive tri­al: IAVI G003, a Phase I tri­al that IAVI will spon­sor. Mod­er­na said ear­ly Wednes­day that par­tic­i­pant screen­ings are start­ing soon for the biotech’s mR­NA HIV vac­cine anti­gen in two places: Rwan­da and South Africa.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER